

OVERVIEW TUESDAY, NOVEMBER 9, 2021

9:00-10:30 am

Live Session I**CART cells for cancer therapy****Keynote** | Rössig, Claudia (Münster University Hospital (UKM), Münster, Germany)**Cell based therapy in hematology****Keynote** | Ciceri, Fabio (IRCCS Ospedale San Raffaele, Milan, Italy)

10:30-11:00 am

Break

11:00 am – 12:00 pm

Poster Session I – Improving the efficacy and safety profile of cell therapies | Biomarkers and immuno monitoring

Poster authors (group 1) are available for live chat.

12:00-12:30 pm

Break

12:30-1:15 pm

Industry Sponsored Session

Supported by Gilead

**DLBCL: CAR-T data and clinical experience**

Glaß, Bertram (Helios Clinic Berlin-Buch, Berlin, Germany)

CAR-T cell therapy in Germany: Clinical experience and status quo

Vucinic, Vladan (University of Leipzig Medical Center, Leipzig, Germany)

MCL: CAR-T data and clinical experience

Heß, Georg (University Medical Center Mainz, Mainz, Germany)

1:15-1:20 pm

Break

1:20-1:45 pm

Industry Flash Talk – Novel immunotherapeutic approaches in multiple myeloma and solid tumors

Supported by GlaxoSmithKline

**Introduction and Belantamab mafodotin trials**

Merz, Maximilian (University of Leipzig Medical Center, Leipzig, Germany)

Targeting NY-ESO-1 for personalized cancer immunotherapy

Schmitt, Michael (Heidelberg University Hospital, Heidelberg, Germany)

Discussion and closure

Merz, Maximilian (University of Leipzig Medical Center, Leipzig, Germany)

1:45-2:15 pm

Break

2:15-3:45 pm

Live Session II**From CARs to TRUCKs: the 4th generation of CAR T cells****Keynote** | Abken, Hinrich (RCI – University of Regensburg, Regensburg, Germany)**Beyond CD19 – CAR-T cells targeting solid tumors****Keynote** | Cathomen, Toni (Medical Center – University of Freiburg, Freiburg, Germany)

3:45-4:15 pm

Break

4:15-5:15 pm

Poster Session II – Cell-based therapy in oncology | Cell-based therapy in hematology | Cancer vaccines and vector-based therapy

Poster authors (group 2) are available for live chat.

OVERVIEW WEDNESDAY, NOVEMBER 10, 2021

9:00-10:30 am	<p>Live Session III</p> <p>Cellular therapy for the treatment of solid cancers</p> <p>Keynote Haanen, John (The Netherlands Cancer Institute, Amsterdam, The Netherlands)</p> <p>Combining cell therapy and immune checkpoint inhibitors</p> <p>Keynote Chabannon, Christian (Institut Paoli-Calmettes, Marseille, France)</p>
10:30-11:00 am	<p>Break</p>
11:00 am - 12:00 pm	<p>Poster Session III – Tumor microenvironment Precision medicine addressing tolerance and inflammation</p> <p>Poster authors (group 3) are available for live chat.</p>
12:00 -12:30 pm	<p>Break</p>
12:30-1:15 pm	<p>Industry Sponsered Session – 3 Immuno-Swords fighting cancer: Inhibition of Pro-Tumor Inflammation, TIM-3-Inhibition and CAR-T-cells</p> <p>Supported by Novartis</p> <p></p> <p>Pro-Tumor Inflammation (PTI) – a new target for fighting cancer. First findings in NSCLC.</p> <p>Kobold, Sebastian (University Hospital of Munich (LMU), Munich, Germany)</p> <p>Immune targeted approaches in myeloid neoplasms and lymphoma</p> <p>Platzbecker, Uwe (University of Leipzig Medical Center, Leipzig, Germany)</p>
1:15-1:20 pm	<p>Break</p>

1:20-2:05 pm	<p>Industry Sponsered Session – New therapy approaches in hematology and immunooncology</p> <p>Supported by Bristol Myers Squibb</p> <p></p> <p>CAR-T-cell therapies for multiple myeloma</p> <p>Kortüm, Martin (University Hospital Würzburg, Würzburg, Germany)</p> <p>State of the art therapy – Immunooncology in 2021 – What is new?</p> <p>Ivanyi, Philipp (MHH, Hannover, Germany)</p> <p>Discussion of all speakers</p>
2:05-2:15 pm	<p>Break</p>
2:15-3:45 pm	<p>Live Session IV</p> <p>Genomic biomarkers of immunotherapy response and monitoring</p> <p>Keynote Dienstmann, Rodrigo (Vall d'Hebron Institute of Oncology, Barcelona, Spain)</p> <p>Precision medicine addressing tolerance and inflammation</p> <p>Keynote Kordasti, Shahram (Kings College London, London, UK)</p>
3:45-4:15 pm	<p>Break</p>
4:15-5:00 pm	<p>Industry Sponsered Session</p> <p>Supported by Amgen</p> <p></p> <p>T cell engaging therapies: Blinatumomab and beyond</p> <p>Bargou, Ralf C. (University Hospital Würzburg, Würzburg, Germany)</p> <p>Klinger, Matthias (Amgen Research (Munich) GmbH, Munich, Germany)</p>